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Abstract
Background: There is an increased risk of premature death in people with severe mental illness (SMI). Respiratory
disorders and cardiovascular disease are leading causes of increased mortality rates in these patients, and tobacco
consumption remains the most preventable risk factor involved. Developing new tools to motivate patients
towards cessation of smoking is a high priority. Information on the motivational value of giving the lung age and
prevention opportunities is unknown in this high-risk population.
Methods/design: This article describes in detail a protocol developed to evaluate an intensive motivational tool,
based on the individual risks of pulmonary damage and prevention opportunities. It is designed as a randomized, 12-
month, follow-up, multicenter study. A minimum of 204 smokers will be included, aged 40 years and older, all of whom
are patients diagnosed with either schizophrenia or bipolar disorder (BD). Chronic obstructive pulmonary disease
(COPD) will be evaluated using spirometry, and the diagnosis will then be validated by a pneumologist and the lung
age estimated. Based on this value, a motivational message about prevention will be issued for the intervention group,
which will be reinforced by individualized text messages over a period of 3 months.
The efficacy of the method and the pulmonary damage variables will be evaluated: smoking cessation at the end
of follow-up will be confirmed by cooximetry, and the COPD diagnosis and the severity of the staging for disease
will be assessed.
Discussion: In the context of community care, screening and early detection of lung damage could potentially
be used, together with mobile technology, in order to produce a prevention message, which may provide
patients with SMI with a better chance of quitting smoking.
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Background
People living with serious mental illness (SMI) reduces
life expectancy by up to 20 years [1]. Tobacco consump-
tion, which is almost three times higher in this group
than in the general population, is the main preventable
risk factor for mortality [2]: half the patients who are un-
able to quit will die of causes related to smoking [3].
Despite the fact that the comorbidity between SMI
and smoking makes it even more difficult to quit [4],
there is growing evidence for the safety and short-term
efficacy of the available treatments [3, 5, 6]. Possible
ways of raising long-term smoking cessation rates in
SMI patients include: improving the pre-treatment prep-
aration phase, combining the available treatments and
increasing the length of the maintenance phase [7].
Getting a patient ready to change their addictive be-
havior requires maximum motivation levels. The deci-
sion to continue smoking or to try to change this habit
depends on a number of factors, including the balance
between the perceived benefits and the risks of contin-
ued smoking. This balance can be influenced by person-
alized messages about the health risks they run, which
serve as a “motivational trigger” [8]. In the general popu-
lation, the most common incentive for giving up smok-
ing is linked to concerns about current or future health
problems [9]. Much less is known about the factors in-
fluencing the decision to quit in people with SMI. People
with schizophrenia [10] and bipolar disorder (BD) [11]
could have a lower appreciation for the health risks asso-
ciated with cigarette smoking. Tidey et al. [12] describe
how psychiatric smokers—parallel to the rest—who
intended to quit, rated the importance of negative health
consequences higher than those who did not. Motivation
to quit smoking in this population might increase if they
are provided with more tailored information on the
negative health consequences of smoking [10, 12].
Respiratory diseases, especially chronic obstructive
pulmonary disease (COPD) and pneumonia, are the
main causes of death in patients with schizophrenia and
BD, alongside cardiovascular disease and cancer [2].
Despite the high rates of smoking addiction, a
higher-risk consumption (starting younger, higher levels
of nicotine dependence and more intense smoking) [13]
and the impact this has on mortality rates, the early
diagnosis of COPD is not currently catered for in the
health care system and studies of the respiratory damage
involved are very rare. Even so, in schizophrenia and
other non-affective psychoses, the existence of impaired
lung function of possible multifactorial origin and the
increased likelihood of obstruction [14] have been re-
ported and the risk of delaying the diagnosis has been
stressed [14]. The Spanish Consensus Statement on
Physical Health in Schizophrenia and BD mentions the
possibility of an increased risk of COPD compared with
the general population [15, 16], although there is limited
information about BD and this is generally inconclusive
due to its lack of statistical power [14].
COPD is the most common respiratory pathology in
the general population, and smoking is its main cause in
the Western countries [17]: it is estimated that half of
those who smoke are likely to suffer from COPD. The
most important changes in lung function occur in the
early stages of the disease, even before the development
of COPD [18]. The reduction in forced expiratory vol-
ume in 1 s (FEV1), when adjusted for age and level of
consumption, is, per se, a high-risk marker of general
mortality [19], cardiovascular mortality [20] and lung
cancer [21]. The main health care challenge we face here
is early diagnosis [22], and quitting smoking is the only
step which is capable of slowing down its progress.
Spirometry is a safe, simple, non-invasive and
cost-effective technique, and is the gold standard test in
the study of pulmonary function and the early diagnosis
of COPD [23]. It can be carried out in the primary care
setting and there is a general consensus over the criteria
for diagnosis and staging [24]; in smokers over 40 years
old, it diagnoses between 21 and 25% of COPD in
asymptomatic patients [25]. Although initially, when
performed in parallel with other biomedical tests, the
value of both test and results in increasing motivation in
the general population to quit smoking proved inconclu-
sive [26], renewed interest has been shown in this tech-
nique following the results of a clinical trial which
informed smokers of the calculation of their “lung age”
and achieved an increase in the cessation rate [8, 27].
However, to our knowledge, there is no evidence avail-
able of how effective this intervention may be in
smokers with SMI.
In the general population, a simple recommendation
by the physician can influence and increase the chances
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of giving up smoking in the long term [28]. In popula-
tions at higher risk, such as smokers with an SMI, the
recommended intervention is the 5 A’s (Ask, Advice, As-
sess, Assist and Arrange) [7] – however, there is still a
need for greater intensity in generating motivation [29].
Currently, mobile technology represents a cost-effective
way of promoting health and preventing disease and the
information it can convey about health can help to
prompt changes in behavior. However, although inter-
ventions through text messages (SMS) are capable of
generating extra motivation to quit smoking in the gen-
eral population, so far there is no evidence in more vul-
nerable populations, including smokers with SMI [30].
The problem of smoking in this population requires
new effective strategies to motivate the patient to attempt
to quit and aim for the ultimate goal of complete abstin-
ence. Although the impact of respiratory disease on the
mortality rates of these patients is clear to see, the possi-
bilities of an early diagnosis of the damage and its influ-
ence on motivating the patient to change are more
problematic. Given these needs and the lack of evidence,
the information based on individual health risks and on
creating chances for prevention provides us with an op-
portunity to assess the situation. It is possible to imple-
ment the study of respiratory damage in an environment
of community care for mental health, and SMS technology
will help to make the message clearer and more forceful.
In a high-risk population, the probability of finding
premature lung damage would be higher. Providing in-
formation on prevention opportunities will help the pa-
tient move forward through the quitting decision. We
therefore propose the following objectives:
To measure the level of undiagnosed lung damage in
smokers with SMI
To evaluate the effectiveness of an intensive anti-
tobacco intervention, which offers individualized infor-
mation on lung damage and possibilities of prevention,
as a way of helping patients diagnosed with schizophre-
nia or BD to quit smoking
Methods/design
Study design
This is a multicenter, open, randomized and prospective
study, with a 12-month follow-up period. Nine Mental
Health Centers from the South of Spain, serving both
rural and urban populations in the provinces of Córdoba,
Jaén, Málaga and Granada, will take part in the study.
The study protocol (version 1: 11/2016) has been ap-
proved by the Ethics Committee of Reina Sof ía Hospital
in Córdoba, Spain, and informed consent will be ob-
tained from each participating patient before recruit-
ment. The http://ClinicalTrials.gov identifier was
NCT03583203.
Recruitment and randomization (see Fig. 1)
This will be a pioneer study in populations with SMI and,
for this reason, reference figures from similar studies [31]
have been used to calculate the sample size, adjusted to
the characteristics and severity of the sample. Abstinence
after 12 months was estimated at 3 and 15% in the control
and experimental branches, respectively. A level of confi-
dence of 95% and a power of 80% is assumed, which re-
quires a minimum of 85 patients per branch, with an
added 20% for possible losses during follow-up.
Recruitment of at least 204 patients who meet all the
inclusion criteria and none of exclusion criteria will be
carried out over 1 year and follow-up appointments will
be arranged after that.
Inclusion criteria: (1) patients aged between 40 and 70
years; (2) confirmed diagnosis of BD or Schizophrenia
according to Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, text revision
(DSM-IV-TR); (3) active smokers who currently con-
sume at least 10 CPD, with a cumulative consumption
of 10 packets/year or more; (4) have signed an informed
consent to participate in the study.
Exclusion criteria: (1) previous respiratory diagnosis
of: asthma, cystic fibrosis, tuberculosis, simple chronic
bronchitis, restrictive pulmonary disease or bronchiec-
tasis; (2) acute respiratory symptoms; (3) heart disease
or advanced oncological processes; (4) existence of a
pathology which makes it advisable not to perform spir-
ometry (recent pneumothorax, recent thoracic or ab-
dominal surgery, aortic aneurysm, unstable angulation,
retinal detachment, facial hemiparesis or oral/dental
problems); (5) patients who, due to their intellectual dis-
ability or mental pathology, do not understand or cannot
be forced to perform spirometry; (6) clinical instability
with results of over 14 points on the Hamilton Depres-
sion Rating Scale (HDRS), a Young Mania Rating Scale
(YMRS) score of over 6 or a Positive and Negative
Syndrome Scale (PANSS) score of over 70.
The randomization will be carried out using the Redcap
[32] program, as implemented by the Bioinformatics Unit
of IMIBIC (the Maimónides Institute of Biomedical
Research in Córdoba, Spain). It will be centralized, per-
formed in permuted blocks and stratified by center, age,
gender and pathology. The ratio will be 1:1 for each arm.
The research staff will have no knowledge of the assign-
ment until the patient signs their informed consent and
has been included in the system (which will automatically
assign the patient, once included, to a particular arm).
Description of the intervention
The intervention will be performed by the regular health
professionals who usually treat the patient (psychiatry and
mental health nursing), after receiving specific training
and after the intervention have been validated by
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specialists from the Addiction Network and the Pneumol-
ogy Service at the Reina Sofía Hospital in Córdoba, Spain.
Control group
The control intervention lasts 30 min and will be struc-
tured around the 5 A’s technique (Ask, Advice, Assess,
Assist and Arrange) [27]. Data will be collected on the
patient’s smoking record, level of consumption and their
individual level of motivation. Their smoking habit, per-
sonal circumstances and the general health risks derived
from their current consumption will be discussed with
the patient following the recommendations of the Treat-
ing Tobacco Guideline [33] and on the basis of the
Motivational Interviewing [34]. The risks and benefits
will be weighed and the patient’s perceived self-efficacy
will be assessed in order to generate greater motivation.
Depending on the degree of motivation, the idea of set-
ting a deadline for the change in habit, specific treat-
ment and regular follow-up will be put forward. In order
to reinforce the message, informative materials stressing
the general health benefits of quitting smoking will be
provided, and patients will be given a direct contact
number to request an urgent appointment for support
and specific treatment, as needed.
Experimental group
This group will go through a spirometry study for a lung
age and obstruction degree determination. The
anti-smoking intervention will follow the same duration
and general structure of the control group. In this case,
when talking about the health risks, personalized infor-
mation about the lung damage and prevention oppor-
tunities will be included. It will teach the patients about
comparing lung age with chronological age and explain
how the formula is calculated and the origin of the dam-
age. After evaluating their COPD, the patients will be in-
formed about its existence and staging. Depending on
the damage found, the generation of motivation will
focus on different prevention methods. Likewise, after
the motivation level is set, the patients will be offered
the option of treatment and regular follow-up. The
intervention will be strengthened by motivational
messages (designed by specialists from our Addiction
Network) in an attempt to give continuity to personal
Screening (Week 0)
The informed consent obtained
Agree to participate Refuse to participate
Randomization 1:1
(center, age, gender and diagnosis)









Visits 3, 4 y 5
(Weeks 16, 28 y 52)
Fig. 1 Flow diagram of study design
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message based on MI—half of which are linked to the
possibility of preventing respiratory damage—and sent
to the patient's mobile phone via SMS during the 3
months after the face-to-face intervention, with a de-
creasing rate: three messages per week in the first
month, and two and one per week in the following
months, respectively (see Table 1 for examples of these
messages) [35]. Patients without mobile phones will re-
ceive a call on their phone to convey the same messages.
Safety protocol
1. The anti-tobacco intervention can only be given to
clinically stabilized patients. In these cases, their
psychiatrist will confirm whether they can be classi-
fied as psychopathologically stable prior to the
intervention scheduled for the second visit
2. Information about individual lung damage will be
offered based on the prevention opportunities and
following the general MI model, as in the rest of
the protocol. To guarantee it, the messages will be
generated based on respiratory variables and by the
team of researchers— psychiatrist, expert physicians
on addiction and pneumologist specialists—and
sent on the Redcap platform to the center
researcher
3. When they are first informed about the
intervention and prior to the start of the intensive
mobile phone intervention with SMS, the patients
are asked once again if they wish to continue with
the study. In each message sent, a phone number is
included where the patient can request not to
receive any more messages if they so wish
4. The patient is given the opportunity to contact the
specialized addiction service network, made up of
physicians who routinely treat patients with SMI
who are trying to quit smoking and do not receive
treatment due to their possible lack of
psychopathological stability
5. The researcher will make a written record of any
COPD diagnosis performed, which, in mild cases, is
sent to the primary care physician and in moderate
or severe cases, to the pneumology service
Patient and public involvement
All the patients will receive enough information about
the study by a resume paper with the principal objectives
and methodology of the research. As was explained in
Fig. 1, only the patients that give their agreement to par-
ticipate will be included in the study. If the patients
want, they will give us their contact details to receive the
principal results published in the future.
Result variables
1. Lung damage variables
2.1 Main variable:
 Presence of COPD (FEV1/forced vital capacity
(FVC) < 0.7, confirmed after bronchodilation)
and staging (FEV1 > 80% – mild, FEV1
50–80% – moderate, FEV1 30–49% – severe)
2.2 Secondary variable:
 Percentage of FEV1 compared with expected
level. Calculation of lung age based on the
Fletcher and Peto [36] model
2. Efficiency variables
2.1 Main variable:
Smoking cessation, defined as self-reported ab-
stinence over the previous 7 days, confirmed by
cooximetry with expired carbon monoxide (CO)
< 10 particles per million (ppm)
2.2 Secondary variables:
 Increased levels of motivation
 Number of attempts to quit and total
duration in days of abstinence, as reported by
the patient
 Smoking cessation objectified by cooximetry
(< 10 ppm) at scheduled follow-up
appointments
 Reduction in the number of cigarettes/day
(CPD) smoked, as reported by the patient
and confirmed by expired CO after 3, 6 and
12 months
Data collection and monitoring (see Fig. 2)
1. Sociodemographic data:
Age, gender, educational level, marital status,
number of children, employment status, place of
residence, home environment (including other
members of the household who smoke) and income
2. Clinical variables:
Table 1 Examples of text messages (SMS) sent to patients in
the intervention group
Wanting to smoke is temporary, but the damage to your lungs is
permanent – Which kind of suffering do you want to choose?
The pleasure of breathing in deeply and enjoying a beautiful spring
morning would be easier with cleaner lungs. How about trying it?
Did that little run down the street leave you breathless? Ever thought
about giving up smoking? Life is much more bearable with clean lungs.
If your lungs could speak, they’d be really angry at how you are treating
them. It’s up to you – you can make your life better.
Better health and lung capacity, more cash to spend and less smelly
clothes. That’s what you gain when you give up smoking. Difficult to
imagine giving up? You’re not alone! Come and see us and we’ll plan
it together.
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STUDY PERIOD
Enrolment Allocation Post-allocation Close-out











Type/Brand of tobacco X
Fagerström Test for Nicotine
Dependence (FTND)
X
Previous attempts to quit X
Current smoking habit
Cigarettes per day (CPD)
Desire to quit X
Self-perception of ability to quit X
Richmond test X
Stage of change X
Application and follow-up on
addictions network X
Psychopathology
Positive and Negative Syndrome
Scale (PANSS) X
Hamilton Rating Scale for
Depression (HDRS) X
Young Mania Rating Scale
(YMRS) X
Hamilton Anxiety Rating Scale
(HAM-A) X





Digit span, forward and
backward (WAIS) X

















pulmonary age, FVC post BD,
FEV1 post BD, FEV1/FVC post




Measurements and vital signs X
FVC: Forced Vital Capacity; FEV 1: Forced expired volume in the first second; BD:
Bronchodilation; GOLD: Global Initiative for Chronic Obstructive Lung Disease
Fig. 2 Scheduled tasks
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 Confirmation of diagnosis. Schizophrenia and
BD sections of the Spanish version of the
Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID-I) [37]
 Psychiatric disease variables, as reported by the
patient and confirmed by their clinical history.
Age of onset, illness duration, number of suicide
attempts and number of hospital admissions in
the last 5 years
 Clinical stability will be assessed by the reference
psychiatrist at each center and evaluated by the
HDRS [38] and YMRS [39] scales for BD and
PANSS [40] for schizophrenia
 Anxiety symptoms of anxiety. Hamilton Anxiety
Rating Scale (HARS) [41]
 Global functioning. Global Activity Assessment
Scale (GAAS) [42]
 Psychopharmacological treatment at study entry
and during the study
3. Comorbidity (from medical history).
Anthropometric measurements and vital signs (by
nurse, following the schedule):
 Hypertension, diabetes, dyslipidemia, peripheral
vascular disease, heart disease and oncological
disease
 Height, weight, Body Mass Index (BMI),
abdominal perimeter, oxygen saturation, blood
pressure and heart rate
4. Smoking habit
 History of consumption: age of onset, years of
consumption and accumulated consumption
(number of packs/year)
 Current consumption and dependency level:
– Type and brand of tobacco and CPD
– Expired CO, reported as ppm, measured
with an MD Diagnostic CO Check+
cooximeter (concentration range 0–99 ppm,
sensitivity 0.1 ppm). The measurements will
be obtained between 11.00 a.m. and 01.00
p.m., with a cut-off point for active
smokers of 10 ppm, as in previous refer-
ences [43].
– Dependence on nicotine, as evaluated by the
Fagerström Test for Nicotine Dependence
(FTND) [44]: mild (0–3), moderate (4–7) and
severe (8–10)
 History of previous attempts to quit smoking
(minimum 24 h trying to quit):
– Record of the number of attempts lasting
more or less than 1 month. Total sum of days
of abstinence reported
– Previous specific treatments, adverse reactions
or psychopathological decompensation
 Motivation to quit smoking:
– Richmond Test [45]: low (0–4), moderate (5–6)
and high (7–10)
– Analogue visual scale from 1 to 10, measuring
the patient’s desire to quit smoking and
perceived self-capacity [46]
– Prochaska and DiClemente’s Stages of Change
(SOC) [47]
 Request for referral to specific treatment of
Addictions Network:
– Number of appointments
– Treatment offered
5. Use of other substances
The consumption of other substances—such as
alcohol, cannabis, cocaine, stimulants,
hallucinogens, heroin, methadone, other opiates or
inhalants—will be measured using the “Drug Use
Table: Individual Substances” section of the Spanish
Addiction Severity Index, 6th version (ASI6) [48]
We will record the age of the first consumption, years
of regular consumption, consumption for 50 or more
days in the patient’s life and consumption over the
last 30 days. Consumption will also be calculated for
caffeine, measured as cups of coffee/day (one cup of
coffee = one energy drink = two cups of tea = three
cups of soft drinks [49]), and for cannabis, measured
as type (resin or leaf), consumption method (joint or
vapor inhalation) and number of joints/year
(52 weeks × number of joints/week/365 × number of
years smoking) [50]. Patients with cocaine or heroin
habits will be noted if the substance is inhaled
6. Physical activity
The amount of physical activity will be calculated
through the self-administered International Physical
Activity Questionnaire (IPAQ), used in its short-
ened version [51] and validated in Spanish [52]. The
unit to measure energy expenditure is the MET
(Metabolic Equivalent of Task), and the total ex-
penditure in METs-minute/week is calculated
7. Neuropsychological evaluation
In order to evaluate neurocognitive functioning and
any possible changes after the intervention, the
Digit Span Test will be used in reverse order or
backwards (WAIS-III) [53], together with parts A
and B of the Trail Making Test [54], which measure
verbal working memory, processing speed and
executive attention, respectively
Spirometry
To validate the equipment used and check its character-
istics, the test and criteria for quality control will be used
for acceptability and repeatability of the results; the
standardization criteria set down by the American Thor-
acic Society and the European Respiratory Society (ATS/
ERS) [55] will be followed (see Table 2).
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Respiratory variables
Respiratory symptoms and impact on quality of life [56]
Severity of dyspnea, using the Modified British Medical
Research Council (mMRC) scale [57]
Statistical analysis
The statistical analysis will include all the patients ran-
domized to both branches according to an intention-
to-treat approach. The main variable for smoking cessa-
tion will be analyzed using the chi-square test for
qualitative variables, which in this case consist of the dif-
ferences between the control and intervention groups.
The effect size will be expressed as relative risk (RR), ab-
solute risk reduction (ARR) and the number needed to
treat (NNT), with the corresponding 95% confidence
interval (CI). The secondary variables will require the
comparison of the average values of the quantitative var-
iables between groups (level of motivation, consumption
of tobacco according to CPD and expired CO) and will
be carried out using Student’s T test and its respective
post-hoc correction tests. The Mann-Whitney U test will
be used for the non-parametric equivalent. The associ-
ation between the quantitative variables will be evaluated
using bivariate correlation tests, such as Pearson’s linear
correlation coefficients (parametric test) or Spearman’s
correlation coefficients (non-parametric test). The re-
spiratory variables for the presence of COPD and its sta-
ging will require a descriptive analysis and the results
will be presented as frequencies and percentages. Logis-
tic regression models will be used for the multivariate
analysis. To control any effects in the comparison be-
tween groups caused by contact with the addiction treat-
ment network or the neurocognitive evaluation, the
variables associated with these events will be collected
and the corresponding adjustments made in the analysis.
Discussion
Motivating smokers with SMI to undertake specific
treatments to quit smoking is certainly challenging, and
even more so to increase their chances of success [58].
In this context, our study may present an opportunity to
develop and evaluate new models of motivational inter-
vention. It is based on estimation of individual health
risks and possible ways of prevention, whereas mobile
technology allows greater intensity of the intervention.
In SMI patients, it is clear that comorbid smoking is
severe and that the risk of respiratory illness increases
the mortality rate. Even so, although we know that early
diagnosis is critical, so far there have been no clinical
recommendations about screening for damage in any
age group or level of tobacco consumption. The pres-
ence of certain symptoms (cough, coughing up mucus,
limited physical activity), the nature of the patients
themselves (who are less likely to visit their physician for
non-psychopathological complaints), and the type of
health care they receive (more focused on mental health
and less on primary care) all hinder an early diagnosis of
the problem. However, in a population made up of pa-
tients with schizophrenia or BD who smoke, assessing
the degree of decline in lung function or level of ob-
struction can provide evidence which can lead to pre-
vention measures to help control serious health threats.
In a population being seriously harmed by smoking to-
bacco, the advent of mobile technology as part of health
care (m-health) gives us a great opportunity to provide
motivation messages at any time and place. The full po-
tential and safety of its use in treating patients with
psychotic disorders have been increasingly recognized in





Nursing team (Mental Health Unit)
Training Accredited traininga given by the pulmonology service of Reina Sofía Hospital, Córdoba, Spain
Skills acquired Calibration, preparing patients, performing maneuvers, bronchodilation and repetition of spirometry
Automatic Validation Automatic validation Maximum of 8 maneuvers before achieving a minimum of 3 maneuvers of an
acceptable standardb Classification and automatic choice of the 2 best curves with repeatability criteriac
Reversibility test Repetition of 3 acceptable maneuvers 15 min after inhalation by bronchodilator (salbutamol, 400 μg)
Quantification
and diagnosis
External Validation External validation curves and volumes are assessed by a single researcher, head of the functional
test unit of the Pneumology Service at the Reina Sofía Hospital, Córdoba, Spain
Volumes Forced vital capacity (FVC), forced expiratory volume (FEV1) and the quotient of the two (FEV1/FVC)
Calculation of
lung age
Automatic and externally verified
Diagnosis
and staging
Presence and degree of respiratory obstruction, according to criteria established by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline
aThe accredited training consisted of learning the theoretical principles behind the test, how to handle and look after the material and how to perform spirometry
maneuvers and secure the selected measurements
bAcceptability criteria: the flow/volume curve must not contain artifacts, must start well and should last for at least 6 s
cRepeatability criteria: the two highest FVC and the two highest FEV1, with a difference between them of less than 0.15 L
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recent years [59]. Even so, although the most basic tools,
such as SMS, have become commonplace in the treatment
of smoking in the general population [60], their possible
use in disadvantaged populations such as smokers with
mental illnesses is still relatively unexplored [61].
Neurocognitive functioning will determine how the pa-
tients receive and make use of this information. In BD and
schizophrenia have been described deficits in attention/
processing speed, working memory and executive func-
tions. These are key elements to maintain goal-directed
behavior in general and stopping nicotine use in particu-
lar. The study design may allow a better understanding of
how these variables influence the possible use of tools pro-
viding medical information in these populations.
Nonetheless, considering their obvious limitations,
the results should be analyzed carefully. Despite the
open design of this study, due to the characteristics
of the intervention under evaluation, the main vari-
ables of efficacy and damage can be measured ob-
jectively through the techniques of cooximetry and
spirometry. The intensity of the experimental inter-
vention can be measured by two factors: the motiv-
ational value of the individualized information and
the importance of keeping up motivation in the fu-
ture. The control intervention is less intense, al-
though much greater than the usual option offered
in this type of population. The intervention is not
designed to propose any specific treatment, but to
prepare the patient for starting treatment and for at-
tending, when ready, the specialized Addictions Net-
work. Once in the real world the type of treatment,
level of adherence and results will all be assessed
objectively.
Community mental health care constitutes the ideal
setting for developing an intervention model based on
prevention. A multidisciplinary team who are familiar
with SMI patients and their health needs can offer
them, through regular follow-up checks, a new way of
approaching the problem of smoking through early
diagnosis and motivation. Studying the lung function
using spirometry is a valid way of doing this, as long
as the health professionals are suitably trained, and
the results are accurately validated and interpreted by
a specialist.
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